Prognostic Nutritional Index is Related to All‐Cause Mortality in Patients With Stage IV Colorectal Cancer Treated With Capecitabine: Single‐Center 24‐Month Observational Study in Vietnam

Abstract

AimTo determine the mortality rate and the predictive value of the prognostic nutritional index (PNI) for all‐cause mortality during the 24 months in patients with stage IV colorectal cancer treated with capecitabine.MethodsWe conducted a study on 87 stage IV colorectal cancer patients treated with capecitabine. Before the day of treatment, all patients were measured CEA and CRP‐hs levels and calculated neutrophil/lympho ratio (NLR) and PNI. Patients were monitored and collected drug side effects and mortality for 24 months.ResultsThe mortality rate of study subjects was 60.9%. CRP‐hs, NLR, and PNI were independent factors associated with 24‐month mortality in patients with stage IV colorectal cancer (p < 0.05 to p < 0.01). At a cut‐off value of 38.51, PNI was a predictor for mortality, with the area under the curve (AUC) of 0.88 and p < 0.001.ConclusionsPNI was a good predictor of all‐cause mortality in patients with stage IV colorectal cancer treated with capecitabine for 24 months.